(Q51928464)

17 April 2018

title

Risperidone (Risperdal): clinical experience with a new antipsychosis drug. (English)

1 reference

17 April 2018

1 reference

Keks NA

1

1 reference

17 April 2018

Culhane C

series ordinal

2

1 reference

17 April 2018

language of work or name

English

0 references

publication date

1 April 1999

1 reference

17 April 2018

Expert Opinion on Investigational Drugs

published in

1 reference

17 April 2018

volume

8

1 reference

17 April 2018

issue

4

1 reference

17 April 2018

page(s)

443-452

1 reference

17 April 2018

Defining treatment refractoriness in schizophrenia

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

The Northwick Park "functional" psychosis study: diagnosis and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

Impact of newer antipsychotics on outcomes in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

An open trial of risperidone in young autistic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

Treatment of Refractory Rapid Cycling Bipolar Disorder With Risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.443

21 January 2018

Identifiers

DOI

10.1517/13543784.8.4.443

1 reference

17 April 2018

1 reference

17 April 2018